• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Lee Charles Benjamin claimed ownership of 292,397 shares (SEC Form 3)

    7/30/25 4:18:48 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MEIP alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Lee Charles Benjamin

    (Last) (First) (Middle)
    9920 PACIFIC HEIGHTS BLVD., SUITE 150

    (Street)
    SAN DIEGO CA 92121

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    07/22/2025
    3. Issuer Name and Ticker or Trading Symbol
    MEI Pharma, Inc. [ MEIP ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 292,397 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    /s/ Justin J. File, as Attorney-in-fact for the Reporting Person 07/30/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MEIP alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MEIP

    DatePrice TargetRatingAnalyst
    7/23/2024Buy → Hold
    Laidlaw
    3/25/2022$4.00 → $1.00Buy → Hold
    Jefferies
    3/25/2022$13.00 → $2.00Overweight → Equal Weight
    Wells Fargo
    3/25/2022$6.00 → $2.00Buy → Hold
    Stifel
    2/3/2022$4.00Buy
    Jefferies
    More analyst ratings

    $MEIP
    SEC Filings

    View All

    SEC Form S-3 filed by MEI Pharma Inc.

    S-3 - MEI Pharma, Inc. (0001262104) (Filer)

    8/6/25 4:43:04 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Inc. filed SEC Form 8-K: Leadership Update

    8-K - MEI Pharma, Inc. (0001262104) (Filer)

    8/6/25 4:05:34 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - MEI Pharma, Inc. (0001262104) (Filer)

    8/5/25 8:05:27 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    MEI Pharma downgraded by Laidlaw

    Laidlaw downgraded MEI Pharma from Buy to Hold

    7/23/24 6:35:29 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma downgraded by Jefferies with a new price target

    Jefferies downgraded MEI Pharma from Buy to Hold and set a new price target of $1.00 from $4.00 previously

    3/25/22 7:17:08 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded MEI Pharma from Overweight to Equal Weight and set a new price target of $2.00 from $13.00 previously

    3/25/22 7:16:36 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $MEIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $MEIP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

    MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or "the Company") today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset, implementing a new strategy built on digital asset infrastructure and long-term capital innovation. This strategic move, developed in partnership with GSR and with guidance provided by Litecoin Creator and MEI Board member Charlie Lee, marks the beginning of MEI's broader institutional treasury ini

    8/5/25 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

    Charlie Lee, the Founder of Litecoin and a lead investor in the PIPE, has joined the Board of Directors of the Company GSR, a preeminent digital asset market maker and lead investor in the private placement, has been appointed to act as the treasury's Asset Manager MEI Pharma will use 100% of the net proceeds to launch its treasury strategy focused on Litecoin, becoming the first and only publicly traded LTC holder on a national exchange MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company" or "MEI") today announced that it has closed its previously announced private placement for the purchase and sale of 29,239,767 shares of common stock (or pre-funded warrants in lieu thereof) at a pric

    7/22/25 4:35:00 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

    Charlie Lee, the Founder of Litecoin and a lead investor in the PIPE, will join the Board of Directors of the Company effective upon the closing of the Private Placement GSR, a preeminent digital asset market maker and lead investor in the private placement, is appointed to act as the treasury's Asset Manager MEI Pharma will use 100% of the net proceeds to launch its treasury strategy focused on Litecoin, becoming the first and only publicly traded LTC holder on a national exchange MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company" or "MEI") today announced that it has entered into securities purchase agreements for a private investment in public equity (PIPE) for the purchase and sale

    7/18/25 8:30:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Lee Charles Benjamin claimed ownership of 292,397 shares (SEC Form 3)

    3 - MEI Pharma, Inc. (0001262104) (Issuer)

    7/30/25 4:18:48 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wood Steven D

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    7/17/25 9:40:54 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Reynolds Thomas C

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    7/17/25 9:39:19 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Anson Funds Management Lp bought $329,331 worth of shares (48,060 units at $6.85) (SEC Form 4)

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    9/25/23 7:43:12 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Funicular Funds, Lp bought $219,554 worth of shares (32,040 units at $6.85) (SEC Form 4)

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    9/25/23 7:41:22 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Anson Funds Management Lp bought $938,226 worth of shares (153,600 units at $6.11)

    4 - MEI Pharma, Inc. (0001262104) (Issuer)

    9/22/23 9:21:02 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Leadership Updates

    Live Leadership Updates

    View All

    MEI Pharma Announces Planned Departure of Chief Financial Officer Brian Drazba and Appointment of Justin File as Successor

    MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, consistent with the Company's succession planning, Brian Drazba's tenure as Chief Financial Officer of the Company will end no later than September 1, 2023, and the Company has hired Justin (Jay) File as his successor. Mr. File joined the Company on June 12, 2023 as Executive Vice President, Finance and will be appointed Chief Financial Officer upon Mr. Drazba's departure. "Brian has been a true asset to MEI providing invaluable fiscal and business leadership as we advanced our clinical programs and executed various transactions, incl

    6/13/23 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Announces Planned Departure of CEO Daniel P. Gold, Ph.D. and Appointment of David M. Urso as Successor

    MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company"), a clinical-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that, in connection with the Company's previously announced succession plan, Daniel P. Gold, Ph.D's tenure as the president and chief executive officer of MEI will end on June 2, 2023 and the Company's board of directors has appointed David M. Urso as his successor. Mr. Urso, who joined the Company in 2014 and has been serving as the company's chief operating officer since 2018, will also join the board of directors. Dr. Gold will remain on MEI's board, where he will continue to share his extensive knowledge and experience with the company.

    6/2/23 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer

    MEI Pharma, Inc. (NASDAQ:MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Anne Frese, an experienced industry executive, joined MEI as chief people officer, a role reporting to Daniel P. Gold, chief executive officer. Ms. Frese will be responsible for the strategy and processes related to building and retaining an exceptional team of professionals. Ms. Frese's appointment is effective immediately. Ms. Frese joins MEI with over 30 years of human resource experience across a variety of industries, including biotech, consulting, hospitality, and engineering. Most recently, she served as chief human resources officer at Vyripharm En

    6/22/22 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Financials

    Live finance-specific insights

    View All

    MEI Pharma Acquires Litecoin, Launches $100M Institutional Treasury Strategy with Charlie Lee and GSR Advising

    MEI Pharma, Inc. (NASDAQ:MEIP) ("MEI" or "the Company") today announced the acquisition of 929,548 Litecoin (LTC) tokens at an average price of $107.58, successfully launching a major institutional treasury strategy with the LTC treasury now valued at approximately $110.4 million as of August 4, 2025. MEI becomes the first U.S.-listed public company to adopt Litecoin as a primary reserve asset, implementing a new strategy built on digital asset infrastructure and long-term capital innovation. This strategic move, developed in partnership with GSR and with guidance provided by Litecoin Creator and MEI Board member Charlie Lee, marks the beginning of MEI's broader institutional treasury ini

    8/5/25 8:00:00 AM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

    Evaluation of Strategic Alternatives is Ongoing MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended December 31, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. As part of this assessment, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first half of fiscal year 2025, the Company commenced c

    2/12/25 4:12:00 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

    Reaffirms Continuation of Evaluation of Strategic Alternatives MEI Pharma, Inc. (NASDAQ:MEIP) (the "Company") today reported results for its quarter ended September 30, 2024. As previously announced in July 2024, the Company is continuing its review and evaluation of potential strategic alternatives. In the review, the Company continues to consider options such as out-licensing opportunities for existing programs and merger and acquisition opportunities, with the goal of maximizing the value of its assets for its stockholders. Oppenheimer & Co., Inc. is serving as the Company's exclusive financial advisor in this process. During the first quarter of fiscal year 2025, the Company comme

    11/12/24 4:05:00 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MEIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

    SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

    2/14/24 4:00:25 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by MEI Pharma Inc. (Amendment)

    SC 13G/A - MEI Pharma, Inc. (0001262104) (Subject)

    2/13/24 5:09:37 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by MEI Pharma Inc. (Amendment)

    SC 13D/A - MEI Pharma, Inc. (0001262104) (Subject)

    11/1/23 5:20:11 PM ET
    $MEIP
    Biotechnology: Pharmaceutical Preparations
    Health Care